Regulatory Action to Protect Access to Hydroxychloroquine for Approved Rheumatic Indications During COVID‐19 in New Zealand

Eamon Duffy(Auckland City Hospital), Thomas Hills(Auckland City Hospital), Nicola Arroll(Auckland District Health Board), Richard Beasley(Medical Research Institute of New Zealand)
Arthritis & Rheumatology
January 10, 2021
10.1002/art.41643
Cited by 1

Related Papers

Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
|PubMed|2001|861
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
|Nature Communications|2021|295
The Stripping of the Altars: Traditional Religion in England, c. 1400-c. 1580.
|The American Historical Review|1994|288
The Golden Legend
|Princeton University Press eBooks|2012|246